Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines - Test2 - elhamkhani - TriplyDB

Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines

Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines

http://www.wikidata.org/entity/Q28304048

about

Impact of endofungal bacteria on infection biology, food safety, and drug development Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Microbiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humans Isolation and characterization of Burkholderia rinojensis sp. nov., a non-Burkholderia cepacia complex soil bacterium with insecticidal and miticidal activities.Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.Evolution of an endofungal lifestyle: Deductions from the Burkholderia rhizoxinica genome.Complete genome sequence of Burkholderia rhizoxinica, an Endosymbiont of Rhizopus microsporus.Comparative genome analysis of rice-pathogenic Burkholderia provides insight into capacity to adapt to different environments and hosts.Endophytic and epiphytic microbes as "sources" of bioactive agents.Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis Isolation and identification of rhizoxin analogs from Pseudomonas fluorescens Pf-5 by using a genomic mining strategy Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells.P glycoprotein (P-gp) and drug resistance--time for reappraisal?Microtubule polarity and dynamics in the control of organelle positioning, segregation, and cytokinesis in the trypanosome cell cycle.Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.Comparative Genomic Insights into Endofungal Lifestyles of Two Bacterial Endosymbionts, Mycoavidus cysteinexigens and Burkholderia rhizoxinica.Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.

P2860

Q21089611-5C5C711A-5924-426B-ACB4-09DECD26F93B Q24679738-B0574716-7C97-4CE7-8821-AF6FDF36F4EE Q26781365-CB579F26-BB08-4170-A760-1D0E87134362 Q27011525-13651C8E-C8A9-4A7D-AA23-CB19FD05443E Q30671528-61B8178F-503B-4B84-BC24-7EA46B4EFD03 Q33495209-41997B31-C85B-44D8-94A5-E09DA02AEA2A Q33888721-6C7DB651-845A-4856-9CCE-383DC4A750FF Q34153359-F3B9BFB4-CA26-4D62-B7E6-AE4172DC8440 Q35576385-168B1A41-0FC3-4FFD-8B15-22AA11558666 Q35635029-F83AA5D5-B9E9-46F0-B868-A479CCB9B5AA Q36081283-512D16D4-EA2A-438D-A193-D4F85B422DEA Q36134934-1CDEA6A9-D1A9-4E5D-A060-6DDAAB0A0AE2 Q36134943-C98E2CE0-D32E-4EFF-9D6F-1CC445966EC0 Q37312187-63871321-BDBB-411E-A020-19237A819876 Q38607762-8047AA4E-75B1-41D4-B25F-FD0CCC8D16DA Q39214217-E26C2663-2F8A-4F06-931A-20ABF1204B3A Q41474990-C9FC51DE-6248-4427-9EB4-67625C6EE20A Q42390230-C7661D55-E612-454E-92CB-B7FDDB733944 Q42490590-44759D70-A5DC-4810-A033-F3F1B709696C Q48773255-2D6F8C0E-55AA-4204-8245-F7135A8FF7F4 Q52316441-063EAF19-3333-47A6-860E-7B509D34B04A Q52769257-D94F8AA2-DB6D-4965-AE83-24639D247A9E Q55043110-904974C5-9C48-462E-A55D-0E2C4B8314C7

P2860

Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines

http://www.wikidata.org/entity/Q28304048

description

1986 nî lūn-bûn

@nan

1986 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1986 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1986年の論文

@ja

1986年学术文章

@wuu

1986年学术文章

@zh-cn

1986年学术文章

@zh-hans

1986年学术文章

@zh-my

1986年学术文章

@zh-sg

1986年學術文章

@yue

name

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@ast

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@en

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@nl

type

label

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@ast

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@en

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@nl

prefLabel

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@ast

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@en

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@nl

P1433

Q28304048-1AF702A5-BD8E-4414-8AAB-B56081991522

P1476

Q28304048-8E297058-39BC-42C8-B9C3-2D6CE05C531C

P2093

Q28304048-1A307FAB-0077-4498-9185-6EB4AA5E83DA

Q28304048-32A840CD-DCE3-4A15-8FA0-3D381EDED396

Q28304048-3F267FF9-1490-4706-8BF1-52F276409FB4

Q28304048-431FDE08-20F0-40A2-BF4F-4D2EED9F9114

Q28304048-5936175A-E56B-47E7-8C45-EC4F3C52C64A

Q28304048-8774BB0A-8BBD-4023-AE79-BE8A79C74CAD

Q28304048-9501577F-FF95-4317-9B2D-0BC2F0E87C90

Q28304048-A6C8C27A-982E-4477-B0AF-E5AD1B8AA3A9

Q28304048-C9E3FDCF-CB83-4E1C-AB11-F4819E2C7C98

Q28304048-E5492924-F2B1-42F5-A842-280B745A098E

P304

Q28304048-C147A5FB-44DF-4F5D-A86A-764D7D390893

P31

Q28304048-3DE9C6CB-347F-455A-A4D5-5CB9D57B665B

P407

Q28304048-353423C3-B688-46C2-8AE3-084CB7E262CF

P433

Q28304048-D85BF2E8-1310-422E-BC28-6FAF7E2752C0

P478

Q28304048-9FE6AFBF-BA8E-4AA5-A59A-DCDFB8D0400C

P577

Q28304048-152C580E-A992-4468-BC88-58EE5BDD1B37

P698

Q28304048-8820FE0D-9912-4298-8B85-5BC803904F53

P921

Q28304048-2DDE527B-EA2D-4F32-B4C5-FEE2602EDF8B

Q28304048-9CE8A47B-1FFB-4673-A063-C3544A1EE057

P1433

Cancer Research

P1476

Rhizoxin, a macrocyclic lacton ...... vincristine-resistant sublines

@en

P2093

F Shimizu

http://www.w3.org/2001/XMLSchema#string

H Iida

http://www.w3.org/2001/XMLSchema#string

I Matsuda

http://www.w3.org/2001/XMLSchema#string

K Sasagawa

http://www.w3.org/2001/XMLSchema#string

S Iwasaki

http://www.w3.org/2001/XMLSchema#string

S Okuda

http://www.w3.org/2001/XMLSchema#string

S Tsukagoshi

http://www.w3.org/2001/XMLSchema#string

T Oh-hara

http://www.w3.org/2001/XMLSchema#string

T Tsuruo

http://www.w3.org/2001/XMLSchema#string

Z Sato

http://www.w3.org/2001/XMLSchema#string

P304

381-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

1986-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

3753552

http://www.w3.org/2001/XMLSchema#string

P921

antibiotic resistance